Loading…
Regulatory exclusivity extends until May 3, 2032.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced on June 6, 2025, that the U.S. Food and Drug Administration (FDA) has granted 10 years of regulatory exclusivity for VOQUEZNA (vonoprazan) Tablets. This exclusivity period will last until May 3, 2032.
The FDA's decision provides Phathom with a significant competitive advantage for its VOQUEZNA product, safeguarding its market position for the next decade. The exclusivity is a critical milestone for the company, reinforcing its commitment to advancing gastrointestinal treatments.
As of the latest available data, Phathom Pharmaceuticals has a free float of 50,305,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.